Research Unit for ORL - Head and Neck Surgery and Audiology, Odense University Hospital, J.B. Winsløws Vej 4, 1st Floor, 5000, Odense C, Denmark.
University of Southern Denmark, Odense, Denmark.
Orphanet J Rare Dis. 2022 Jan 6;17(1):8. doi: 10.1186/s13023-021-02160-1.
Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant disorder characterized by several clinical symptoms including epistaxis, arteriovenous malformations (AVM), and telangiectasia. In 2018, European Reference Network for Rare Vascular Diseases (VASCERN) recommended five outcome measures for HHT-patients to guide health care providers, some with limited experience in treating HHT, and thereby maximizing the number of HHT-patients receiving good care. The outcome measures cover the following aspects: (1) 90% of the patients should receive a pulmonary AVM (PAVM) screening; (2) 90% of the patients should receive written advice on nosebleed; (3) 70% should be assessed for iron deficiency; (4) 100% of the patients should receive written advice on antibiotic (AB) prophylaxis prior to dental and surgical procedures, and (5) 100% of relevant patients should receive written advice on pregnancy. We have introduced the outcome measures as Benchmarks in our HHT-centre and wanted to evaluate the extend of implementation we have achieved. We constantly struggle to secure the best possible treatment of our HHT-patients.
The study was a non-interventional retrospective study. Data was collected manually from patient records and from the Danish HHT-database.
A total of 180 HHT-patients were included, all diagnosed in the period from January 1st, 2016, to December 31st, 2020. All patients were screened for PAVM. We could confirm that 66% of patients who had epistaxis received thoroughly advice. Assessment for iron deficiency was performed in 80% of the adult patients. Thoroughly advice on AB prophylaxis was documented in 75%. Thoroughly advice on pregnancy was documented in 80% of female patients 15-45 years of age. There were no significant differences over time for any of the outcome measures.
The Danish HHT-centre reached the target threshold for outcome measures 1 and 3. It could not be documented that the target thresholds for outcome measures 2, 4, and 5 were achieved. As information and education are a very important part of HHT care, focus on and documentation that all patients receive the relevant advice must be a priority in order to ensure best care.
遗传性出血性毛细血管扩张症(HHT)是一种常染色体显性遗传疾病,其特征是存在多种临床症状,包括鼻出血、动静脉畸形(AVM)和毛细血管扩张。2018 年,欧洲罕见血管疾病参考网络(VASCERN)推荐了 5 项用于 HHT 患者的结果衡量指标,以指导医疗保健提供者,其中一些提供者在治疗 HHT 方面经验有限,从而使更多的 HHT 患者得到良好的治疗。这些结果衡量指标涵盖以下方面:(1)90%的患者应接受肺动静脉畸形(PAVM)筛查;(2)90%的患者应接受鼻出血书面建议;(3)70%的患者应评估缺铁情况;(4)100%的患者应在进行牙科和外科手术前接受抗生素(AB)预防措施的书面建议,以及(5)100%的相关患者应接受妊娠书面建议。我们已经将这些结果衡量指标引入到我们的 HHT 中心作为基准,并希望评估我们已经达到的实施程度。我们一直在努力为我们的 HHT 患者提供尽可能好的治疗。
该研究是一项非干预性回顾性研究。数据是从患者记录和丹麦 HHT 数据库中手动收集的。
共纳入 180 例 HHT 患者,所有患者均于 2016 年 1 月 1 日至 2020 年 12 月 31 日期间确诊。所有患者均接受 PAVM 筛查。我们可以确认,有 66%曾发生鼻出血的患者接受了彻底的建议。80%的成年患者接受了缺铁评估。75%的患者有关于 AB 预防措施的彻底建议。80%的 15-45 岁女性患者有关于妊娠的彻底建议。任何结果衡量指标在时间上均无显著差异。
丹麦 HHT 中心达到了结果衡量指标 1 和 3 的目标阈值。无法证明结果衡量指标 2、4 和 5 的目标阈值已达到。由于信息和教育是 HHT 护理的重要组成部分,因此必须将重点放在确保所有患者都能获得相关建议的工作上,并将其作为确保最佳护理的优先事项。